CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ISTA Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ISTA Pharmaceuticals, Inc.
50 Technology Drive
Phone: (949) 788-6000p:949 788-6000 Irvine, CA  92618  United States Ticker: ISTAISTA

This company ceased filing statements with the SEC on 6/18/2012.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
ISTA Pharmaceuticals, Inc. (ISTA) is a commercial-stage, multi-specialty pharmaceutical company. The Company is engaged in developing, marketing and selling its own products in the United States and Puerto Rico. ISTA is a prescription eye care business in the United States and has an allergy drug franchise. ISTA manufactures its finished good products through third-party contracts. ISTA in-licenses or acquires new products and technologies to add to its internal development. Its products and product candidates seek to treat allergy and diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye and ocular and nasal allergies. It has four products available for sale in the United States and Puerto Rico: BROMDAY (bromfenac ophthalmic solution) 0.09%, BEPREVE (bepotastine besilate ophthalmic solution) 1.5%, ISTALOL (timolol maleate ophthalmic solution) 0.5% and VITRASE (hyaluronidase injection).
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/201212/31/2011YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer VicenteAnido 59 6/6/2012 12/19/2001
Chief Financial Officer, Vice President - Corporate Development Lauren P.Silvernail 53 3/1/2003 3/1/2003
Vice President - Finance, Chief Accounting Officer Brian G.Drazba 50
10 additional Officers and Directors records available in full report.

Business Names
Business Name
ISTA
ISTA Pharma, Ltd. (United Kingdom)
ISTA Pharmaceuticals
ISTA Pharmaceuticals, Inc.
Visionex Pty. Ltd. (Singapore)

General Information
Number of Employees: 330 (As of 1/31/2012)
Outstanding Shares: 41,906,005 (As of 3/31/2012)
Shareholders: 121
Stock Exchange: NASD
Federal Tax Id: 330511729
Fax Number: (949) 788-6010


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023